证券代码：301166 证券简称：优宁维 投资者关系活动记录表 上海优宁维生物科技股份有限公司 编号：2022-012 | --- | --- | --- | |-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：301166 证券简称：优宁维 上海优宁维生物科技股份有限公司 投资者关系活动记录表 编号：2022-016 | --- | --- | --- | --- | |-----------------------------|--------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：301166 证券简称：优宁维 上海优宁维生物科技股份有限公司 投资者关系活动记录表 编号：2022-026 | --- | --- | --- | --- | |-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Group 1: Company Overview - Shanghai Youningwei Biotechnology Co., Ltd. focuses on life sciences and has established a nationwide direct sales channel to reach end customers [1] - The company has a strong professional team with over 17 years of industry experience, which enhances its market insight and competitive edge [1] Group 2: Supplier and Market Dynamics - The company maintains stable relationships with major suppliers, with a low supplier concentration, minimizing risks from trade frictions [1] - The company’s self-owned brands, Aibixin and Lebeishi, have seen a revenue growth of 124% year-on-year in 2021, indicating a strong market demand [2] Group 3: Impact of COVID-19 - The pandemic has negatively impacted operations, particularly in regions with strict lockdowns, but the company has adapted by ensuring continuous production and supply chain management [2] - The company has implemented measures to mitigate the impact of COVID-19, including remote operations and enhancing online engagement [2] Group 4: Logistics and Distribution - The company has modernized its logistics system, utilizing third-party logistics for distribution and ensuring efficient management of product shelf life and traceability [3] - New warehouses in cities like Chengdu and Nanjing have been established to improve delivery efficiency and respond to customer needs more effectively [2] Group 5: Future Investments and Development - The company plans to invest 280 million yuan in the Nanjing R&D and production base, which is expected to enhance its product development capabilities [3] - Future focus areas include accelerating R&D for self-owned products, enhancing sales teams, and expanding logistics capabilities to improve service delivery [4]

证券代码：301166 证券简称：优宁维 上海优宁维生物科技股份有限公司 编号：2022-021 | --- | --- | --- | --- | |---------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：301166 证券简称：优宁维 上海优宁维生物科技股份有限公司 投资者关系活动记录表 编号：2022-025 | --- | --- | --- | |-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：301166 证券简称：优宁维 上海优宁维生物科技股份有限公司 投资者关系活动记录表 编号：2022-023 | --- | --- | --- | |---------------------|---------------------------------------------------------------|------------------------------------| | 投资者关系活动 类别 | 特定对象调研 媒体采访 新闻发布会 现场参观 其他 ( 电话会议) | 分析师会议 业绩说明会 路演活动 | | | 隋欣 国信证券资管 | | | | 赵子淇 | 国联安基金管理有限公司 | | | 杜向阳 西南证券 | | | | 张殊豪 西南证券 | | | | 杨 芳 国盛证券 | | | | 张 晓 华商基金管理有限公司 | | | | 李海伟 华商基金管理有限公司 | | | | 贺 鑫 安信证券 | | | | 陈泉龙 大成基金管理有限公司 | | | | 陈 颖 | 上海理成资产管理有限公司 | | | | | | 参与单位名称及 | 洪 露 兰石资产 | | ...

证券代码：301166 证券简称：优宁维 上海优宁维生物科技股份有限公司 投资者关系活动记录表 编号：2022-022 | --- | --- | --- | |-----------------------------|---------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 类别 | 特定对象调研 媒体采访 新闻发布会 现场参观 其他 ( 电话会议) | 分析师会议 业绩说明会 路演活动 | | | 罗佳荣 广发证券 | | | | 张 韡 汇添富 | | | | 曹聪聪 光大证券 | ...

证券代码：301166 证券简称：优宁维 上海优宁维生物科技股份有限公司 投资者关系活动记录表 编号：2022-019 | --- | --- | |-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Group 1: Company Overview - The company is Shanghai Youningwei Biotechnology Co., Ltd., with stock code 301166 and abbreviation Youningwei [1]. - The investor relations activity took place on June 15, 2022, via an online survey [2]. Group 2: Business Development and Strategy - The company is accelerating the construction of distribution centers in Beijing and Guangzhou, with the Nanjing center already operational, serving as a major distribution hub [2]. - A total investment of 280 million yuan has been allocated for the Nanjing R&D and production base, which commenced construction in February 2022 [3]. - The company plans to enhance its product lines, focusing on antibodies and related reagents, while also expanding into molecular and cellular products [3]. Group 3: Financial Performance - The company's self-owned brands, including Aibixin and Lebeishi, experienced a revenue increase of 124% year-on-year in 2021 [3]. - The company aims to maintain stable revenue growth by increasing investment in R&D and production, particularly for self-developed products [3]. Group 4: Market Position and Future Outlook - The life sciences service industry is characterized by low market concentration, indicating potential for future consolidation [3]. - The company is committed to enhancing its marketing, R&D, and management capabilities to improve its supply chain and overall operational efficiency [3].